Centessa Pharmaceuticals Gets FDA Clearance for LB101 Clinical Trial

By Chris Wack

Centessa Pharmaceuticals Plc said Thursday that it has received clearance for its Investigational New Drug application from the U.S. Food and Drug Administration to initiate a Phase 1/2a first-in-human, clinical trial of LB101 for the treatment of solid tumors.

The company said its LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody targeting solid tumors.

LB101 is the first product candidate developed using the company's proprietary LockBody technology, which is designed to selectively drive potent effector function activity, such as CD47, in the tumor microenvironment while avoiding systemic toxicity.

Centessa shares were up 9% at $4.18 in premarket trading.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

01-26-23 0932ET